TREATMENT STRATEGY FOR INITIAL OF RELAPSING AND FREQUENT RELAPSING STEROID SENSITIVE AND STEROID DEPENDENT MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
https://doi.org/10.24884/1561-6274-2013-17-3-17-25
Abstract
According to the native and foreign literature Strategy of corticosteroid and cytostatic treatment of relapsing and frequent relapsing steroid sensitive and steroid dependent (with steroid toxicity) minimal change nephritic syndrome (MCNS) in children on the onset stage is presented. Administrating details of alkylate compounds (chlorbutin, cyclophosphan), calcineurin synthesis inhibitors (cyclosporine A), nucleotide synthesis inhibitors (mizoribine, micophenolate mofetil) of MCNS in children was discussed. Clinical experience and new scientific findings stipulated change tactic of choice of immunosuppressive preparation, its dosage and treatment duration in MCNS in children.
About the Author
N. D. Savenkova
ГБОУ ВПО Санкт-Петербургский государственный педиатрический медицинский университет Министерства здравоохранения Российской Федерации
Russian Federation
Russian Federation
References
1. Международная статистическая классификация болезней и проблем, связанных со здоровьем (Х пересмотр ВОЗ, 1995, Женева). Класс XIV. Раздел болезней мочеполовой системы (N00-N99)
2. International study of kidney disease in children. Nephrotic syndrome in children: prediction of hystopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 1978;13:159–163
3. International study of kidney disease in children. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. А Report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98: 561–564
4. Churg J, Sobin LH. Renal disease (classification and atlas of glomerular disease). Igaku-Shoin, Tokyo-New York, 1982; 359
5. Fogo A. Renal Pathology. In Pediatric Nephrology. Senior Editor E. Avner. IPNA. Springer-Verlag 2009; Vol 1: 565-598
6. Pavenstadt H, Kriz W. and Kretzler M. Cell Biology of Glomerular Podocyte. Physol Rev 2003;15:253-307
7. Patrakka J, Jahdenkari, Koskimies O, Holmberg C, Wartiovaara J, Jalanko H. The number of podocite slit diaphragms is decreased in minimal change nephrotic syndrome. Pediatr res 2002; 52:349-355
8. Gbadegesin R. and Smoyer W. Nephrotic Syndrome. Comprehensive Pediatric Nephrology. Editors D.Geary, F. Schaefer. MOSBY 2008; 205-218
9. Hodson E, Alecsander S, and Graf N. Steroid-Sensitive Nephrotic Syndrome/ In Comprehensive Pediatric Nephrology. Editors D.Geary, F. Schaefer. MOSBY 2008; 239-256
10. Niauted P. Steroid-Sensitive Idiopatic Nephrotic Syndrome in Children. In Pediatric Nephrology. Editors E.Avner, W.Harmon, P.Niauted. LIPPINCOTT-WILLIAMS-WILKINS, 2004: 544-556
11. Niauted P, Boyer O. Idiopathic Nephrotic Syndrome in Children: Clinical Aspects. In Pediatric Nephrology, 6- th edition. Editors E. Avner, W.Harmon, N Yoshikawa. IPNA. Springer-Verlag, 2009; 1:667-702
12. Савенкова НД, Папаян АВ. Нефротический синдром в практике педиатра. Эскулап, СПб., 1999; 256
13. Игнатова МС, Шатохина ОВ. Диагностика и лечение нефротического синдрома у детей. Руководство для врачей. М: ООО «Медицинское информационное агенство», 2009; 300
14. Савенкова НД, Папаян АВ, Батракова ИВ. Нефротический синдром с минимальными изменениями у детей. Папаян А.В., Савенкова Н.Д. Клиническая нефрология детского возраста. Левша.Санкт-Петербург, СПб., 2008; 279-302
15. Цыгин АН. Нефротический синдром. Детская нефрология. Под ред Э. Лоймана, А.Н.Цыгина, А.А.Саркисяна. Литтерра, М., 2010; 123-140
16. Cambon-Thomsen A, Bouisson F, Abbal M et al. HLA and B12 in idiopathic nephrotic syndrome of children. Differences between steroid sensitive and steroid resistant patients. Pathol Biol 1986; 34: 725-730
17. Konrad M, Mytilineos J, Ruder H, Opelz G et al: HLA-DR 7 predicts the response to alkylating agents in steroid-sensitive nephrotic syndrome. Pediatr Nephrol 1997; 11:16-19
18. Папаян АВ, Серга АП. Иммунопатология нефротического синдрома при гломерулонефрите с минимальными изменениями (липоидный нефроз). Педиатрия 1985; 11: 66-69
19. Батракова ИВ, Савенкова НД. Особенности течения нефротического синдрома с минимальными изменениями у детей с повышением специфических IgE. Матералы Х съезда педиатров России. Москва, 8-10 февраля, 2005. Вопросы современной педиатрии. 2005; 4:23
20. Shimada M, Araya C, Rivald C et al. Minimal change disease: a «two-hit» podocyte immune disorder? Pediatr Nephrol 2011;26:645-649
21. Tain YL, Chen TY, Yang KD. Implication of serum Ig E in childhood nephritic syndrome. Pediatr Nephrol 2003; 18 (12): 1211-1221
22. Тур ИИ, Савенкова НД, Назаров ПГ и др. Сравнительное исследование IgE-антител, IFNγ- и IL-4 у детей с нефротическим синдромом с минимальными изменениями и атопическим дерматитом. Нефрология 2007; 4:69-74
23. Arbeitsgemeinschaft fur Padiatrische Nephrologie Short versus standart prednisolone therapy for initial treatment of idiopatic nephrotic syndrome in children. Lancet 1988; 1: 380-383
24. Arbeitsgemeinschaft fur Padiatrische Neophrologie. Minimal change nephrotic syndrome: long prednisone versus standard prednisone therapy. Pediatr Nephrol 1990; 4: 60
25. Brodehl J. Conventional therapy for idiopathic nephrotic syndrome in children Clin Nephrol 1991; 35(1): 8-15
26. Ehrich JHH, Brodehl J. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Long versus standard prednisone therapy for initial of idiopathic nephrotic syndrome in children Eur J Pediatr 1993; 152: 357-361
27. Bargman JM. Management of minimal lesion glomerulonephritis Evidence-based recommendations. Kidney int 1999; 70 (55): 3-16
28. А Report of the International Study of Kidney Disease in Children. Early identification of frequent relapsers among children with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 1982; 101:514-518
29. Lande MB, Leonard MB Variabiliy among pediatric nephrologists in the initial therapy of nephritic syndrome. Pediatr Nephrol 2000; 14: 766-769
30. Gipson DS, Massengill SF, Yao L et al. Management of childhood onset nephritic syndrome. Pediatrics 2009; 124: 747- 756
31. Teeninga N, Kist-Van Holthe JE, Van Rusvuk N et al. Effect of extended Prednisolone treatment from threetosix monts, with equal cumulative doses, on childchood nephritic syndrome: A national-wide randomized controlled trial. Abstracts. The 45th Annual Meeting of the ESPN, on September 6th-8th 2012, Krakow, Poland. Pediatr Nephrol 2012; 27:1637
32. Clark A, Barratt TM. Steroid-responsive nephrotic syndrome. Edited by Т.М. Barratt, E.D. Avner, WE Harman. Pediatric nephrology. LIPPINCOTT-WILLIAMS-WILKINS, 1998; 731-747
33. Andersen RF, Thragt N, Noergard K et al (2010) Early age at debut is a predictor of steroid-dependetn and frequent relapsing nephritic syndrome. Pediatr Nephrol 2010; 25: 1299-1304
34. Van Husen M, Kemper MJ. New therapies in steroidsensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011; 26: 881-892
35. Vester U, Kranz B. Cyclophosphamide in steroid-sensitive nephrotic syndrome outcome and outlook. Pediatr Nephrol 2003; 18: 661-664
36. Kemper J, Altrogge H, Ludwig K et al. Unfavorable response to cyclophosphamide in steroid-dependent nephritic syndrome. Pediatr Nephrol 2000;14: 772-775
37. Arbeitsgemeinschaft fur Padiatrische Nephrologie: Cyclophosphamide treatment of steroid dependent nephrotic syndrome: Comparison of eight week with 12 week course. Arch Dis Child 1987; 62: 1102-1106
38. Grup W, Makker SP, Ingelfinger JR: Chlorambucil treatment of frequently relapsing nephrotic syndrome. N Engl J Med 1976; 295: 746-749
39. Azib S, Macher M, Kwon T et al. Cyclophosphamide in steroid dependent nephrotic syndrome. Pediatr Nephrol 2011; 26: 927-932
40. Zagury A, Louse A, de Ollveira et al. Long- term follow-up after cyclophosphamide therapy in steroid dependent nephrotic syndrome. Pediatr Nephrol 2011; 26: 915-920
41. Tejani A, Buttk,Trechtman H. Cyclosporin A induced remission of frequently relapsing nephrotic syndrome in children. Kidney Int1988; 33:729-734
42. Tanaka Н, Yoshikava N, Kitano Y. Long-term Cyclosporin treatment in children with steroid dependent nephrotic syndrome. Pediatr Nephrol 1999; 7: 249-252
43. Батракова ИВ, Савенкова НД. Цитостатическая терапия нефротического синдрома с минимальными изменениями у детей. Нефрология 2004; 2:98-105
44. Rinaldi S, Sesto A, Barsotti P et al. Cyclosporine therapy monitored with abbreviated area under curve in nephrotic syndrome. Pediatr Nephrol 2005; 20: 25-29
45. Игнатова МС, Турпитко ОЮ, Харина ЕА, Обухова ВА. Результаты многоцентрового изучения эффективности циклоспорина А при нефротическом синдроме у детей. Педиатрия 2008; 87:93-97
46. Matsumoto H, Hakao T, Okada T et al. Initial remission inducing effect of very low-olose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japannese adults. Clin Nephrol 2001; 55(2): 143-148
47. Wang W, Xia Y, Mao J et al. Treatment of tacrolimus or cyclosporine A in children with idiopathic ntphrotic syndrome. Pediatr Nephrol 2012; 27: 2073-2079
48. Ulinski Т, Bruno Ranchin, Marie-Helene Said et al. Switch from cyclosporin A (Cy A) to mycophenolate mofetil improves kidney function in children with nephrotic syndrome and Cy Ainduced nephrotoxicity. Abstracts book from the World Congress of Nephrology June 8-12, 2003 Berlin. Nephrol Dial Transplant 2003; 18 (suppl 4): 261
49. Honda M. Nephrotic syndrome and mizoribine in children. Pediatrics International (2002) 44: 196-198
50. Fujinaga S, Hirano D, Nihizaki N et al. Single daily higt –dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporin administration. Pediatr Nephrol 2011; 26: 479-483
51. Novak L, Frank R, Vento S et al. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2005; 20(9) 1265-1268
52. Caropreso MR, Ferreti AV, Margieri G et al. Mycophenolate mofetil in the treatment of children with steroid-dependent nephrotic syndrome. Nephrol Dial Transplant 2003; 18(Suppl 4): 65
53. Hogg R, Fizgibbons L, Bruick J et al. Multicenter trial of mycophenolate mofetil (MMF) in children with steroid dependent (SD) or frequently relapsing (FR) nephrotic syndrome (NS). Report of the southwest pediatric nephrology study group. Abstract book from the World Congress of Nephrology. June 8-12, Berlin (2003). Nephrol Dial Transplan 2003; 18 (Suppl. 4): 261
54. Barletta GM, Smoyer WE, Bunchmann TE et al. Use of mycophenolate mofetil in steroid-dependent and-resistant nephrotic syndrome. Pediatr Nephrol 2003; 18:833-837
55. Vallejo GG, Liern MM, De Reyes VV et al. Enteric Coated Mycophenolate Sodium in Patients with steroid-dependent nephrotic syndrome. Congress Abstracts the 15th Congress of the International Pediatric Nephrology Association. August 29- September2, 2010, New York. Pediatr Nephrol 2010; 25:1886
56. Banerjee S, Pahari A, Sengupta J, Patnaik S. Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil. Pediatr Nephrol 2013; 28:93-97
57. Tendron A, Gouyon J, Decramer S. In utero exposure to immunosuppressive drugs: experimental and clinical studies Pediatr Nephro. 2002; 17(2): 121-130
58. Kemper MJ, Moeller C, Rink N, Van Husen M, MullerWiefel D. Treatment of Referactory Steroid Sensitive Nephrotic Syndrome (SSNS) with Rituximab. Abstracts the 14th Congress of the International Pediatric Nephrology Association. 31 August4 September 2007, Budapest, Hungary. Pediatr Nephrol 2007; 22:1445
59. Sellier-Leclere A-L, Macher M-A, Loirat C. et al. Rituximab in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2010; 25: 1109-1115
60. Fujinaga S, Hirano D, Nishizaki N et al. Single infusion of Rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long term cyclosporine. Pediatr Nephrol 2010; 25: 539-544
61. Prytula A, Iijima K, Kamei К et al. Rituximab in refractory nephrоtic syndrome. Pediatr Nephrol 2010; 25:461-468
62. Musielak A, Silska M, Lipkowska K et al. Rituximab as a non-standart immunosuppressive therapy in children with nephrotic syndrome – a single pediatric nephrology center experience. Abstracts the 44-th Annual Scientific Meeting of the European Society for Paediatric Nephrology. 14-17 September 2011, Cavtat–Dubrovnik. Pediatr Nephrol 2011; 26:1646
63. Haffner D, Fischer D. Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 2009; 24:1433-1438
Review
For citations:
Savenkova N.D. TREATMENT STRATEGY FOR INITIAL OF RELAPSING AND FREQUENT RELAPSING STEROID SENSITIVE AND STEROID DEPENDENT MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN. Nephrology (Saint-Petersburg). 2013;17(3):17-25. (In Russ.) https://doi.org/10.24884/1561-6274-2013-17-3-17-25
Views:
544
Email this article 